Rigel Pharmaceuticals, Inc. provides preliminary unaudited revenue guidance for the fourth quarter of 2021. For the year, the company expects total revenue of approximately $20.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.35 USD | -8.00% |
|
+20.49% | -28.62% |
25/06 | Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split | MT |
25/06 | Sector Update: Health Care Stocks Advance Pre-Bell Tuesday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.62% | 20Cr | |
+20.03% | 13TCr | |
+23.61% | 12TCr | |
+23.26% | 2.79TCr | |
-18.07% | 2.1TCr | |
-15.13% | 1.69TCr | |
-14.81% | 1.62TCr | |
+9.78% | 1.48TCr | |
-46.10% | 1.48TCr | |
+52.34% | 1.41TCr |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter of 2021